Showing results (161-170 of 200) with videos related to

Sort By:
Pageof 20
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 14, 2005
A panel discussion of controversies and challenges in the adjuvant treatment of colon cancerEduardo Díaz-Rubio García, Albert Abad Esteve, Antonio Antón Torres, et al.
BMC Cancer|April 21, 2025
Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancerManuel Valladares-Ayerbes, Marta Toledano-Fonseca, Begoña Graña, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJean-Yves Douillard, Salvatore Siena, James Cassidy, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2021
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trialFernando Rivera, Marta Izquierdo-Manuel, Pilar García-Alfonso, et al.
BMC Cancer|September 9, 2014
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancerSonia Molina-Pinelo, Amancio Carnero, Fernando Rivera, et al.
NEJM Evidence|February 6, 2024
Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic CancerAlfredo Carrato, Roberto Pazo-Cid, Teresa Macarulla, et al.
Acta Oncologica (Stockholm, Sweden)|July 9, 2008
Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancerFernando Rivera, María Eugenia Vega-Villegas, Carlos López, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2013
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trialJosep Tabernero, Rocio Garcia-Carbonero, James Cassidy, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 7, 2021
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Manuel Benavides, Auxiliadora Gómez-España, Pilar García-Alfonso, et al.
The Lancet. Oncology|April 15, 2022
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 studyLuis A Diaz, Kai-Keen Shiu, Tae-Won Kim, et al.
Pageof 20